Cargando…
Abstinence Rate, Adverse Events and Withdrawal Symptoms after Varenicline Use and Predicting Factors of Smoking Abstinence: A Multicentre Single-State Study in Malaysia
(1) Background: Varenicline is a widely prescribed agent in smoking cessation. However, the abstinence rate, the incidence of adverse events and withdrawal symptoms, have not been widely studied locally. This study aimed to determine the prevalence of smoking abstinence, adverse events and withdrawa...
Autores principales: | Choo, Shea Jiun, Chang, Chee Tao, Tangiisuran, Balamurugan, Latif, Mohd Faiz Abdul, Sanusi, Nor Aida, Harun, Sabariah Noor |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9265789/ https://www.ncbi.nlm.nih.gov/pubmed/35805417 http://dx.doi.org/10.3390/ijerph19137757 |
Ejemplares similares
-
Effect of Extending the Duration of Prequit Treatment With Varenicline on Smoking Abstinence: A Randomized Clinical Trial
por: Hawk, Larry W., et al.
Publicado: (2022) -
Neuroplasticity of the extended amygdala in opioid withdrawal and prolonged opioid abstinence
por: Kaplan, Gary B., et al.
Publicado: (2023) -
Seven-Day Continuous Abstinence Rate from Smoking at 1, 2, or 3 Years after the Use of Varenicline
por: Kim, Jin Se, et al.
Publicado: (2015) -
The efficacy of varenicline in achieving abstinence among waterpipe tobacco smokers – study protocol for a randomized controlled trial
por: Zahid, Raana, et al.
Publicado: (2017) -
Adherence to Varenicline and Abstinence Rates for Quitting Smoking in a Private Health Promotion Center-Based Smoking Cessation Clinic
por: Lee, Jin-Young, et al.
Publicado: (2012)